



What is claimed is:

- I. A compound having a structure according to Formula (I):



(I)

wherein:

- a. each R^1 is selected from the group consisting of lower alkyl, CN, and halo;
- b. m is an integer 1 or 2;
- c. Q is  ;
- d. each R^2 is H;
- e. R^3 is selected from the group consisting of: H, alkyl, OH, OR^4 , and SR^4 ;
- f. X is CH;
- g. Y is N;
- h. A is selected from the group consisting of: C(O) and N-G;
- i. B is selected from the group consisting of: C(O) and N-G;
- j. Provided that one and only one of A or B is C(O);
- k. G is selected from the group consisting of: alkyl, cycloalkyl, aryl, heteroalkyl, heterocycloalkyl, heteroaryl, OR^4 and $S(O)_2R^4$;
- l. each R^4 is independently selected from H, lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, cycloalkenyl, aryl, heteroalkyl, heteroalkenyl, heteroalkynyl, heterocycloalkyl, heterocycloalkenyl, and heteroaryl;
- m. each R^5 is independently selected from H, lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, cycloalkenyl, aryl, heteroalkyl, heteroalkenyl, heteroalkynyl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, OR^4 , and $S(O)_2R^4$;

or an optical isomer, diastereomer or enantiomer for Formula (I), or a pharmaceutically-acceptable salt thereof.

2. The compound according to Claim 1 wherein G is selected from the group consisting of: alkyl, aryl, heteroalkyl, and heterocycloalkyl.
3. The compound according to Claim 1 wherein R⁴ is selected from the group consisting of: phenyl, alkyl, and heteroaryl.
4. The compound according to Claim 3 herein each R¹ is independently selected from the group consisting of: F, Cl, CF₃, CN, and CH₃.
5. The compound according to Claim 4 herein A is C(O).
6. The compound according to Claim 4 herein B is C(O).
7. A compound selected from the group consisting of:
 - 4-(4-Fluorophenyl)-3-(2-methylsulfanyl-pyrimidin-4-yl)-2*H*-isoxazol-5-one;
 - 2-Ethoxymethyl-4-(4-fluorophenyl)-3-(2-methylsulfanyl-pyrimidin-4-yl)-2*H*-isoxazol-5-one;
 - 4-(4-Fluorophenyl)-2-(4-methylpiperazine-1-carbonyl)-3-(2-methylsulfanyl-pyrimidin-4-yl)-2*H*-isoxazol-5-one;
 - 4-(4-Fluorophenyl)-2-(morpholine-4-carbonyl)-3-(2-methylsulfanyl-pyrimidin-4-yl)-2*H*-isoxazol-5-one;
 - 2-Allyl-4-(4-fluorophenyl)-3-(2-methylsulfanyl-pyrimidin-4-yl)-2*H*-isoxazol-5-one;
 - 2-Ethoxymethyl-4-(4-fluorophenyl)-3-[2-(2-hydroxyphenoxy)-pyrimidin-4-yl]-isoxazol-5-one;
 - 2-Ethoxymethyl-4-(4-fluorophenyl)-3-[2-(3-hydroxyphenoxy)-pyrimidin-4-yl]-isoxazol-5-one;

2-Ethoxymethyl-4-(4-fluorophenyl)-3-(2-phenoxy-pyrimidin-5-yl)-2*H*-isoxazol-5-one;

3-{2-[(2-cyano)-methylamino]-2-ethoxymethyl-4-(4-fluorophenyl)-pyrimidin-4-yl}-2*H*-isoxazol-5-one;

3-[2-(Benzylamino)-pyrimidin-4-yl]-2-ethoxymethyl-4-(4-fluorophenyl)-isoxazol-5-one;

(*R*)-2-Ethoxymethyl-4-(4-fluorophenyl)-3-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-isoxazol-5-one;

(*S*)-2-Ethoxymethyl-4-(4-fluorophenyl)-3-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-isoxazol-5-one;

N-(2-{4-[2-Ethoxymethyl-4-(4-fluorophenyl)-5-oxo-2,5-dihydro-isoxazol-3-yl]-pyrimidin-2-yloxy}-phenyl)-acetamide;

2-Ethoxymethyl-4-(4-fluorophenyl)-3-[2-(2-methylamino-phenoxy)-pyrimidin-4-yl]-2*H*-isoxazol-5-one;

2-Ethoxymethyl-4-(4-fluorophenyl)-3-{2-[(2-hydroxyphenyl)-methylamino]-pyrimidin-4-yl}-2*H*-isoxazol-5-one;

2-Allyl-4-(4-fluorophenyl)-3-(2-methylsulfanyl-pyrimidin-4-yl)-2*H*-isoxazol-5-one;

2-Allyl-4-(4-fluorophenyl)-3-(2-phenoxy-pyrimidin-5-yl)-2*H*-isoxazol-5-one;

[4-(4-Fluorophenyl)-5-oxo-3-(2-phenoxy-pyrimidin-4-yl)-5*H*-isoxazol-2-yl]-acetaldehyde;

2-(*N,N*-Dimethylaminoethyl)-4-(4-fluorophenyl)-3-(2-phenoxy-pyrimidin-4-yl)-2*H*-isoxazol-5-one;

2-(*N,N*-Diethylaminoethyl)-4-(4-fluorophenyl)-3-(2-phenoxy-pyrimidin-4-yl)-2*H*-isoxazol-5-one;

4-(4-Fluorophenyl)-2-(2-piperazin-1-ylethyl)-3-(2-phenoxy-pyrimidin-4-yl)-2*H*-isoxazol-5-one;

4-(4-Fluorophenyl)-2-(2-piperidin-1-ylethyl)-3-(2-phenoxy-pyrimidin-4-yl)-2*H*-isoxazol-5-one;

4-(4-Fluorophenyl)-2-(2-morpholin-4-ylethyl)-3-(2-phenoxy-pyrimidin-4-yl)-2*H*-isoxazol-5-one;

4-(4-Fluorophenyl)-3-(2-phenoxy-pyrimidin-4-yl)-2-(2-pyrrolidin-1-ylethyl)-2*H*-isoxazol-5-one;

2-[2-(2-Amino-ethylamino)ethyl]-4-(4-fluorophenyl)-3-(2-phenoxy-pyrimidin-4-yl)-2*H*-isoxazol-5-one;

4-(4-Fluorophenyl)-2-[2-(2-hydroxy-ethylamino)ethyl]-3-(2-phenoxy-pyrimidin-4-yl)-2*H*-isoxazol-5-one;

[2-(2-Dimethylamino-ethylamino)-4-(4-fluorophenyl)-3-(2-phenoxy-pyrimidin-4-yl)-2*H*-isoxazol-5-one;

(2-Ethylamino-ethyl)-4-(4-fluorophenyl)-3-(2-phenoxy-pyrimidin-4-yl)-2*H*-isoxazol-5-one; and

3-(4-Fluorophenyl)-4-(2-methylsulfanyl-pyrimidin-4-yl)-2*H*-isoxazol-5-one.

8. A pharmaceutical composition comprising:
 - (a) a safe and effective amount of a compound of Claim 21; and
 - (b) a pharmaceutically-acceptable carrier.
9. A method for treating osteoarthritis, the method comprising administering to said subject a safe and effective amount of a compound of Claim 1.
10. A method for treating rheumatoid arthritis, the method comprising administering to said subject a safe and effective amount of a compound of Claim 1.
11. A method for treating congestive heart failure, the method comprising administering to said subject a safe and effective amount of a compound of Claim 1.